Eprosartan Prevents Secondary Stroke Better, Study Says

Published Online: Friday, July 1, 2005

According to a study conducted at St. Josefs Hospital, Cloppenburg, Germany, the angiotensin receptor blocker eprosartan proved more effective at preventing secondary stroke in patients than the calcium antagonist nitrendipine, although the 2 showed equal effectiveness at reducing overall blood pressure. The study included 1405 patients who had suffered a transient ischemic attack or stroke in the past 2 years, and who randomly received both medications and were monitored for an average of 2.5 years.

In both groups, normotensive blood pressure readings were reached within 3 months of treatment. During the follow-up period, there were 461 cases of a cardiovascular or cerebrovascular event or death. Of those cases, 206 were from the eprosartan group, and 255 from the nitrendipine group. Analysis confirmed that eprosartan was associated with a lower incidence of cardiovascular and recurrent cerebrovascular events than nitrendipine.

Latest Articles
Having trouble getting your hands on FluMist?
Novartis is paying $390 million to settle charges that it paid kickbacks to pharmacies to encourage drug sales.
Anxiety sensitivity has been linked to more debilitating asthma symptoms and greater functional limitations.
Nasal corticosteroid sprays do not seem to be viable treatments for the common cold.
Latest Issues